Compare IDEXX Laboratories, Inc. (IDXX) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Newmont Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while Newmont Corporation trades at $91.78 (market cap $95.23B). The key difference: Newmont Corporation is far larger — about 2.1× IDEXX Laboratories, Inc.'s market cap, and Newmont Corporation pays a 1.17% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NEM | |
|---|---|---|
Market Cap | $44.48B | $95.23B |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $131.95 |
52-Week Low | $520.87 | $59.86 |
Enterprise Value | $45.38B | $91.98B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Newmont Corporation (NEM) trades at $89.52, down 0.2% over 24 hours, with technical indicators showing a bearish trend. The company reported strong fundamentals with Q1 2026 EPS of $2.90 beating expectations of $2.07, revenue growth to $22.67 billion in 2025, and robust cash flow from operations of $10.33 billion. Analyst sentiment remains overwhelmingly positive with 28 buy ratings and a consensus price target of $139.22, suggesting significant upside potential from current levels.
The outlook for Newmont is favorable due to strong earnings momentum, attractive valuation multiples (P/E of 11.63), and projected revenue growth to $25.0 billion in 2026. Key risks include exposure to gold price volatility, rising unit costs pressuring margins, and execution challenges in production growth. The stock presents a compelling opportunity for value-oriented investors given the disconnect between current price and analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
